The differences may be significant in the 1-, 2-, and 3-year DFS rates and reduce over time due to various factors such as the development of treatment resistance.
← all excerpts
Clinical value of epidermal growth factor receptor mutation testing in peripheral blood of patients with non-small cell lung cancer.
1
—
—